We should have a dream: Unlocking the workings of the genome in cutaneous T-cell lymphomas

Clinical Lymphoma and Myeloma

Volumn 9, Issue 6, 2009, Pages 409-411

  Porcu, Pierluigi ^a   Wong, Henry ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; BCR ABL PROTEIN; BELINOSTAT; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; IMATINIB; ISOTRETINOIN; PANOBINOSTAT; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR; VORINOSTAT;

CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHROMATIN; CHROMOSOME 17Q; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG MECHANISM; EPIGENETICS; GENE EXPRESSION PROFILING; GENE FUNCTION; GENOME; HUMAN; MOLECULAR BIOLOGY; MYCOSIS FUNGOIDES; PHILADELPHIA 1 CHROMOSOME; PROMYELOCYTIC LEUKEMIA; SEZARY SYNDROME; SHORT SURVEY; TRANSCRIPTION REGULATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 72549086619     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.081     Document Type: Article

References (16)

1. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007; 117:2067-2074
2. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009; 113:3655-3665
3. Warrell RP Jr, He LZ, Richon V, et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90:1621-1625
4. Lo-Coco F, Breccia M, Diverio D. The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16:503-520
5. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009; 114:1150-1157
6. Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol 2004; 51:25-32.
7. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19:2456-2471 (Pubitemid 32391217)
8. Richardson SK, Newton SB, Bach TL, et al. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. Am J Hematol 2007; 82:792-797
9. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-728
10. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98:2865-2868
11. Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 2005; 37:265-274
12. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous Tcell lymphoma. J Clin Oncol 2007; 25:3109-3115
13. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109:31-39
14. van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113:127-136
15. Duvic M, Olsen EA, Breneman D, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2009; 9:412-416
16. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28(suppl 1):S24-31.